Novartis drug firm faces Turkey bribe probe
Turkish prosecutors have launched an investigation into alleged corruption by Swiss pharmaceutical giant Novartis, the Anatolia news agency said on Friday.
The probe follows reports in the Turkish press which alleged Novartis paid bribes of $85 million (75 million euros) via a consulting company to representatives of the Turkish health ministry in order to "unfairly acquire a market share".
Contacted by AFP, Novartis said it had no comment on the report. But it said a previous probe into Novartis in Turkey, sparked by a complaint by a whistleblower, was dropped by Turkish authorities after
Novartis's own internal investigation in 2014 found no wrongdoing.
The drugmaker said last week it had reached a deal with US authorities to pay $25 million (22.4 million euros) to settle claims that its Chinese units bribed healthcare professionals to boost sales.
And the US last year fined the group $390 million for granting kickbacks to pharmacies that recommended the company's drugs.
Comments
See Also
The probe follows reports in the Turkish press which alleged Novartis paid bribes of $85 million (75 million euros) via a consulting company to representatives of the Turkish health ministry in order to "unfairly acquire a market share".
Contacted by AFP, Novartis said it had no comment on the report. But it said a previous probe into Novartis in Turkey, sparked by a complaint by a whistleblower, was dropped by Turkish authorities after
Novartis's own internal investigation in 2014 found no wrongdoing.
The drugmaker said last week it had reached a deal with US authorities to pay $25 million (22.4 million euros) to settle claims that its Chinese units bribed healthcare professionals to boost sales.
And the US last year fined the group $390 million for granting kickbacks to pharmacies that recommended the company's drugs.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.